US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Spdr S&P Pharmaceuticals Etf

63.64

-0.1400-0.22%

Post-market: 63.640.00000.00%19:30 EDT

Volume:312.54K

Turnover:19.92M

Market Cap:509.14M

PE:24.65

High:64.49

Open:64.30

Low:63.43

Close:63.78

52wk High:74.35

52wk Low:46.90

Shares:8.00M

Float Shares:8.00M

Volume Ratio:1.27

T/O Rate:3.91%

Dividend:0.27

Dividend Rate:0.43%

EPS(TTM):2.58

EPS(LYR):-0.1280

ROE:42.40%

ROA:0.26%

PB:1.19

PE(LYR):-497.13

Loading ...

Overview Company News Filings

Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained

Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment

Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion

Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars

BMO starts Exelixis at Market Perform into patent cliff

AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape

HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/XPH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"Spdr S&P Pharmaceuticals Etf","latestPrice":63.64,"timestamp":1790971200000,"preClose":63.78,"halted":0,"volume":312539,"hourTrading":{"tag":"盘后","latestPrice":63.64,"preClose":63.64,"latestTime":"19:30 EDT","volume":44219,"amount":2814101.16,"timestamp":1790983804557,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0021950454687990053,"floatShares":8000270,"shares":8000270,"eps":2.581957,"marketStatus":"Market Closed","change":-0.14,"latestTime":"10-02 16:00:00 EDT","open":64.3,"high":64.49,"low":63.425,"amount":19920636.722737,"amplitude":0.016698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.78,"sharesOutstanding":5750270,"nav":63.651736,"aum":486952968.3,"dividendRate":0.00429,"bidAskSpread":0.001632,"preHourTrading":{"tag":"盘前","latestPrice":64.7054,"preClose":63.78,"latestTime":"08:52 EDT","volume":50,"amount":3235.27,"timestamp":1790945577460,"change":0.9254,"changeRate":0.014509,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":63.64,"preClose":63.64,"latestTime":"19:30 EDT","volume":44219,"amount":2814101.16,"timestamp":1790983804557,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.274639270131969,"impliedVol":0.1293,"impliedVolPercentile":0.3068},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","floatShares":8000270,"roa":"0.26%","roe":"42.40%","lyrEps":-0.128016,"volumeRatio":1.274639270131969,"shares":8000270,"dividePrice":0.273,"high":64.49,"amplitude":0.016698,"preClose":63.78,"low":63.425,"week52Low":46.9,"pbRate":"1.19","psRate":"232.40","week52High":74.345,"institutionHeld":0,"latestPrice":63.64,"eps":2.581957,"divideRate":0.00429,"volume":312539,"delay":0,"ttmEps":2.581957,"open":64.3,"prevYearClose":56.01,"prevWeekClose":66.09,"prevMonthClose":65,"prevQuarterClose":65,"fiveDayClose":66.09,"twentyDayClose":71.03,"sixtyDayClose":70.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XPH\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"XPH","amount":0.04164,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-23","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-23"},{"date":"2026-06-22","symbol":"XPH","amount":0.059045,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XPH","amount":0.060954,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XPH","amount":0.113024,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XPH","amount":0.102634,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.091273,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.026956,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.085023,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.07227,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-21","value":0.019429,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XPH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1147221461","title":"Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, \"Buy\" Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1147221461","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147221461?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:54","pubTimestamp":1790672068,"startTime":"0","endTime":"0","summary":"Citi issued a research report stating that Sino Biopharmaceutical (01177), through its subsidiary Chia Tai Tianqing, has entered into a strategic partnership with German pharmaceutical company STADA...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","C","BK4588","BK4207","LU2360032135.SGD","LU0477156953.USD","LU0106831901.USD","LU0320765646.SGD","IE00BSNM7G36.USD","LU1668664300.SGD","BK1589","LU0098860793.USD","LU0170899867.USD","PPH","LU0310800965.SGD","LU1267930227.SGD","BK4559","HK0000165453.HKD","BK1515","BK4585","LU1244550494.USD","LU2322448957.HKD","LU0130517989.USD","LU1992135399.USD","LU2473716301.USD","BK1521","FTXO","LU0052756011.USD","LU0980610538.SGD","BK4566","IYF","LU2417539215.USD","01177","LU2322448791.USD","BK1191","LU1992135472.HKD","LU2272731600.USD","LU2272731865.HKD","LU0130102774.USD","LU2125154778.USD","TFNS","LU2456880835.USD","IBB","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU1244550221.USD","LU0203347892.USD","BK4534","LU0072461881.USD","LU0314106906.USD","LU1144417596.USD","LU1791807156.HKD","IE00BZ08YS42.EUR","LU0162691827.USD","LU1162221912.USD","BK4504","LU2462157665.USD","LU1506573853.SGD","LU1366192091.USD","LU2236285917.USD","LU0128525689.USD","LU1244550577.SGD","LU2125154935.USD","XPH","IE00B5TLWC47.USD","LU1201861249.SGD","LU1074936037.SGD","LU0648001328.SGD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188705505","title":"Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705505","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705505?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:03","pubTimestamp":1790647387,"startTime":"0","endTime":"0","summary":"Shares of Sino Biopharmaceutical (01177) climbed nearly 4%, rising 3.64% to HK$5.695 as of press time, with turnover reaching HK$89.7588 million.On the news front, Sino Biopharmaceutical announced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2272731865.HKD","IE00BZ08YS42.EUR","IE00B5TLWC47.USD","FXE","HK0000165453.HKD","LU2322448957.HKD","KCAI","LU2473716301.USD","IE00BZ08YT58.USD","VXUS","LU1992135399.USD","BK1515","XPH","EURmain","LU2272731600.USD","BK4585","BK1521","EUO","BK4588","LU2272731782.SGD","IE00BZ08YR35.GBP","NBIE","IBB","BK1191","PPH","LU2322448791.USD","LU1992135472.HKD","01177","MEURmain","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131230465","title":"Patent Expirations and R&D Gaps Create a Looming Biologic Shortfall, Potentially Costing the U.S. Healthcare System $189 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1131230465","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131230465?lang=en_us&edition=fundamental","pubTime":"2026-09-18 09:54","pubTimestamp":1789696466,"startTime":"0","endTime":"0","summary":"A recent industry analysis warns that over the next decade, nearly 90% of biologic drugs losing their market exclusivity will lack a corresponding biosimilar in development, creating a significant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135472.HKD","BK4588","PPH","BK4585","IBB","LU2272731782.SGD","LU1992135399.USD","LU2322448791.USD","IE00B5TLWC47.USD","159891","LU2473716301.USD","XPH","LU2272731865.HKD","LU2272731600.USD","LU2322448957.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188259168","title":"Fosun Pharma's Subsidiary Sees Regulatory Acceptance for Denosumab Biosimilar Candidate HLX14","url":"https://stock-news.laohu8.com/highlight/detail?id=1188259168","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188259168?lang=en_us&edition=fundamental","pubTime":"2026-09-11 17:50","pubTimestamp":1789120228,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) has announced that the drug registration application for its self-developed denosumab biosimilar, HLX14 (recombinant anti-RANKL fully human...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1992135472.HKD","BK0060","BK0239","BK0196","600196","LU2272731600.USD","LU2272731865.HKD","LU2272731782.SGD","02196","BK1593","BK1515","BK0096","BK4585","BK0183","LU2322448957.HKD","BK0175","LU2473716301.USD","LU1992135399.USD","IE00B5TLWC47.USD","BK0012","PPH","BK4588","BK0188","XPH","BK1191","BK0028","LU2322448791.USD","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","LU2272731865.HKD","PPH","BK4585","BK1574","LU2272731600.USD","XPH","HK0000320264.USD","LU2272731782.SGD","159992","IBB","LU2322448791.USD","LU2322448957.HKD","LU1992135399.USD","IBBQ","IE00B5TLWC47.USD","LU1992135472.HKD","LU2473716301.USD","HK0000320223.HKD","02696","HK0000165453.HKD","LNGR","HK0000306685.HKD","MEDX","BK4588","BK1161","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","WDNA","JDOC","SBIO","BBH","GSKH","NVIB","MNTL","AZNH","LFSC","HRTS","GNOM","LLYX","IBRN","MEDI","PBPH","GNMX","MDTX","BBP","IBB","MEDX","GDOC","GPCR","PJP","BME","BIB","CANC","FBT","CURE","FHLC","TBXU","IBBQ","PTH","IEIH","IDNA","RSPH","XPH","JHMH","FTXH","CNCR","APXH","PSCH","IBBJ","SURI","PINK","SYNB","HYLG","PBE","PSIL","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNY","GSKH","FHLC","IBBQ","APXH","PSCH","HYLG","SURI","PSIL","GPCR","FTXH","LENZ","BBP","CURE","RSPH","PBPH","TBXU","AZNH","BIB","MEDI","GDOC","MEDX","BBH","IBB","NVIB","JHMH","LLYX","IBBJ","FBT","GNOM","HRTS","SYNB","JDOC","XPH","PINK","MNTL","MDTX","FXH","SBIO","LFSC","BME","PTH","PJP","CANC","WDNA","IBRN","GNMX","PBE","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191429118","title":"Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars","url":"https://stock-news.laohu8.com/highlight/detail?id=1191429118","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191429118?lang=en_us&edition=fundamental","pubTime":"2026-08-20 11:00","pubTimestamp":1787194818,"startTime":"0","endTime":"0","summary":"Shares of HENLIUS (02696) climbed nearly 8% during intraday trading, with the stock last up 6.87% at HK$70.05, recording a turnover of HK$16.47 million. The company recently announced a framework...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000165453.HKD","LU2272731600.USD","LU1992135472.HKD","PPH","LU2322448957.HKD","IE00B5TLWC47.USD","LU2272731865.HKD","02696","HK0000320223.HKD","BK1161","BK4585","XPH","LU2473716301.USD","HK0000320264.USD","LU2272731782.SGD","IBB","BK4588","LU2322448791.USD","HK0000306701.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492411","title":"BMO starts Exelixis at Market Perform into patent cliff","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492411?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:30","pubTimestamp":1787085023,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durabl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JDOC","LU1992135399.USD","BK4585","IE00B5TLWC47.USD","FBT","BME","BK4588","PBPH","MEDX","LU2272731865.HKD","APXH","PPH","IBB","BK4532","LU2322448957.HKD","USRD","RXL","LU2473716301.USD","LU1992135472.HKD","PJP","BK4207","SYNB","CURE","LU2322448791.USD","PTH","BMO","BBH","FXH","FHLC","TRUH","LU2272731782.SGD","AZNH","XPH","IYH","GSKH","FTXH","MEDI","EXEL","RSPH","BK4139","IHE","RXD","LU2272731600.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167771958","title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1167771958","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167771958?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:33","pubTimestamp":1785713585,"startTime":"0","endTime":"0","summary":"AstraZeneca PLC (AZN.US) has been in early-stage discussions about acquiring Bristol-Myers Squibb (BMY.US), a move that could create one of the world's largest pharmaceutical companies, according to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","LU1093756325.SGD","LU1718418525.SGD","BMY","PPH","IEHS","LU1267930573.SGD","LU0306806265.USD","LU0225771236.USD","LU0096364046.USD","LU1868837136.USD","IHE","IE00BJT1NW94.SGD","BK4007","FHLC","BK4585","LU2237443895.HKD","LU0882574055.USD","LU0306807586.USD","LU1868836914.USD","AZN","LU2237443978.SGD","LU0114720955.EUR","LU1093756168.USD","LU2272731782.SGD","LU2242646821.SGD","LU0456855351.SGD","MEDI","LU2473716301.USD","RXL","LU1670710588.SGD","LU0109394709.USD","LU0320765992.SGD","LU0432979614.USD","LU1992135399.USD","LU0225284248.USD","LU0985481810.HKD","LU2272731865.HKD","LU0889565916.HKD","LU1261432733.SGD","LU1323610961.USD","PILL","LU2462157665.USD","FTXH","LU2596442595.SGD","LU2237443549.SGD","LU1989771016.USD","IE00BFTCPJ56.SGD","IE00B3T34201.USD","RXD","LU2133065610.SGD","LU2322448791.USD","LU1074936037.SGD","LU0289739699.SGD","LU2089984988.USD","LU1883839398.USD","LU2242652126.USD","BK4568","LU0868494617.USD","LU1829250122.USD","LU0321505868.SGD","LU0029864427.USD","LU0237698245.USD","BK4581","LU1430594728.SGD","LU2322448957.HKD","LU1992135472.HKD","IE00BJJMRZ35.SGD","LU2456880835.USD","BK4534","LU1670711123.USD","LU2236285917.USD","XPH","LU2468319806.SGD","LU0061475181.USD","IE0009355771.USD","AZNH","LU2237443382.USD","LU0128525929.USD","LU0708994859.HKD","BK4532","LU2272731600.USD","JHMH","FXH","LU0267386448.USD","LU0321505439.SGD","LU1868837300.USD","LU1670710661.SGD","LU0310800379.SGD","LU2125154778.USD","LU1585245621.USD","BK4588","IE00B2B36J28.USD","LU2237443622.USD","LU2417539215.USD","XBIX","LU1670711040.USD","LU1868836591.USD","LU1571399168.USD","BK4559","IE00BSNM7G36.USD","LU2125154935.USD","IE0002141913.USD","IE00B5TLWC47.USD","LU1983299246.USD","CURE","LU1291159041.SGD","LU1868836757.USD","LU0058720904.USD","LU1032466523.USD","IE00BFXG1179.USD","SYNB","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122606361","title":"HENLIUS Initiates First Patient Dosing in China for Phase 1 Study of Cetuximab Biosimilar HLX05-N in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1122606361","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122606361?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:32","pubTimestamp":1783503169,"startTime":"0","endTime":"0","summary":"HENLIUS (ASX: 02696) has announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1 clinical study of its self-developed cetuximab injection...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2322448791.USD","HK0000165453.HKD","LU1992135472.HKD","HK0000306701.USD","02696","IBB","BK4585","XPH","LU2473716301.USD","LU2272731600.USD","BK4588","LU2322448957.HKD","LU2272731782.SGD","HK0000320223.HKD","HK0000320264.USD","LU2272731865.HKD","HK0000306685.HKD","PPH","IE00B5TLWC47.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}